title: Towards optimal treatment of ductal carcinoma in situ.
abstract: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with a variable biological behavior which is difficult to accurately predict using the current clinico-pathological parameters. Randomized controlled trials have demonstrated that adjuvant radiotherapy (RT) reduces the risk of local recurrence after adequate local excision of DCIS. Tamoxifen may be considered as an adjuvant endocrine treatment in patients with high risk estrogen receptor positive disease. There is however a growing consensus that RT can be safely omitted in a subgroup of patients with favorable biological features in order to avoid overtreatment. The sentinel node biopsy is not routinely indicated but should be considered in women undergoing mastectomy for DCIS. The discovery of molecular signatures that accurately predict the biological behavior of this common malignancy will facilitate a personalized treatment approach in the future.
authors.affiliation: Christina Choy, Kefah Mokbel, The London Breast Institute, The Princess Grace Hospital, London W1U 5NY, United Kingdom.
authors.forename: Christina
authors.initials: C
authors.lastname: Choy
authors.affiliation: Christina Choy, Kefah Mokbel, The London Breast Institute, The Princess Grace Hospital, London W1U 5NY, United Kingdom.
authors.forename: Kefah
authors.initials: K
authors.lastname: Mokbel
keywords: Ductal carcinoma in situ; Radiotherapy; Tamoxifen; Treatment
references.citation: J Natl Cancer Inst. 2011 Mar 16;103(6):478-88
references.pmid: 21398619
references.citation: J Natl Cancer Inst. 2013 May 15;105(10):701-10
references.pmid: 23641039
references.citation: Clin Cancer Res. 2014 Jan 15;20(2):344-57
references.pmid: 24150233
references.citation: Breast Cancer Res Treat. 2011 May;127(1):1-14
references.pmid: 21327465
references.citation: Eur J Radiol. 2013 Oct;82(10):1731-7
references.pmid: 23743052
references.citation: Lancet Oncol. 2011 Jan;12(1):21-9
references.pmid: 21145284
references.citation: Radiother Oncol. 2011 Aug;100(2):195-9
references.pmid: 21411161
references.citation: Am J Surg. 2003 Oct;186(4):337-43
references.pmid: 14553846
references.citation: Cancer. 2011 Mar 15;117(6):1156-62
references.pmid: 21381008
references.citation: Int J Surg Oncol. 2012;2012:347385
references.pmid: 22675624
references.citation: J Clin Oncol. 2013 Nov 10;31(32):4054-9
references.pmid: 24043739
references.citation: BMC Cancer. 2010 Apr 29;10:171
references.pmid: 20429922
references.citation: Mol Oncol. 2013 Oct;7(5):859-69
references.pmid: 23890733